Citigroup Inc Tg Therapeutics, Inc. Call Options Transaction History

Citigroup Inc

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 12, 2024	BUY	$13.32 - $19.19 $466,200 - $671,650	35,000 Added 87.72%	74,900 $1.33 Million
Q1 2024 May 10, 2024	SELL	$13.02 - $21.3 $65,100 - $106,500	-5,000 Reduced 11.14%	39,900 $606,000
Q4 2023 Feb 09, 2024	SELL	$6.68 - $18.81 $33,400 - $94,050	-5,000 Reduced 10.02%	44,900 $766,000
Q3 2023 Nov 09, 2023	SELL	$8.36 - $26.5 $29,259 - $92,750	-3,500 Reduced 6.55%	49,900 $417,000
Q2 2023 Aug 10, 2023	BUY	$15.48 - $35.0 $826,632 - $1.87 Million	53,400 New	53,400 $1.33 Million
Q4 2022 Feb 09, 2023	SELL	$5.01 - $11.83 $2.69 Million - $6.35 Million	-536,800 Reduced 80.5%	130,000 $1.54 Million
Q3 2022 Nov 10, 2022	BUY	$4.57 - $8.4 $762,276 - $1.4 Million	166,800 Added 33.36%	666,800 $3.95 Million
Q2 2022 Aug 10, 2022	BUY	$3.74 - $10.66 $1.4 Million - $4 Million	375,000 Added 300.0%	500,000 $2.13 Million
Q4 2021 Feb 10, 2022	BUY	$15.2 - $35.51 $1.9 Million - $4.44 Million	125,000 New	125,000 $2.38 Million

337

87.7M

2.35M

1.7M

Ticker TGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 145,274,000
Market Cap $4.18B
Description
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.